These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34027269)

  • 21. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
    Heath L; Aveyard P; Tomlinson JW; Cobbold JF; Koutoukidis DA
    Hepatol Commun; 2022 Oct; 6(10):2623-2633. PubMed ID: 35903833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
    Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
    Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
    Corey KE; Vuppalanchi R; Wilson LA; Cummings OW; Chalasani N;
    Aliment Pharmacol Ther; 2015 Feb; 41(3):301-9. PubMed ID: 25429853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis.
    Kovalic AJ
    J Clin Exp Hepatol; 2022; 12(4):1057-1068. PubMed ID: 35814516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis-A Pilot Study.
    Stojanovic M; Raskovic S; Milivojevic V; Miskovic R; Soldatovic I; Stankovic S; Rankovic I; Stankovic Stanojevic M; Dragasevic S; Krstic M; Diamantopoulos AP
    J Cardiovasc Dev Dis; 2021 Dec; 8(12):. PubMed ID: 34940542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients.
    Huang JF; Dai CY; Huang CF; Tsai PC; Yeh ML; Hsu PY; Huang SF; Bair MJ; Hou NJ; Huang CI; Liang PC; Lin YH; Wang CW; Hsieh MY; Chen SC; Lin ZY; Yu ML; Chuang WL
    Hepatol Int; 2021 Oct; 15(5):1136-1147. PubMed ID: 34386935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between serum cytokeratin 18 and N-terminal procollagen III propeptide in patients with biopsy-proven nonalcoholic fatty liver disease.
    Kaya S; Boydak M; Aydin M; Aras İ
    Biotech Histochem; 2024 Aug; ():1-7. PubMed ID: 39092622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type III and type I procollagen markers in fibrosing alveolitis.
    Lammi L; Ryhänen L; Lakari E; Risteli J; Pääkkö P; Kahlos K; Lähde S; Kinnula V
    Am J Respir Crit Care Med; 1999 Mar; 159(3):818-23. PubMed ID: 10051256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
    Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
    Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Rossi SJ; Paredes AH; Trotter JF; Bashir MR; Guy CD; Banerjee R; Jaros MJ; Owers S; Baxter BA; Ling L; DePaoli AM
    Hepatology; 2020 Apr; 71(4):1198-1212. PubMed ID: 30805949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.
    Abignano G; Blagojevic J; Bissell LA; Dumitru RB; Eng S; Allanore Y; Avouac J; Bosello S; Denton CP; Distler O; Ferraccioli G; Jordan S; Matucci-Cerinic M; Ong V; Messenger M; Hutchinson M; Buch MH; Emery P; Del Galdo F
    Rheumatology (Oxford); 2019 Feb; 58(2):254-259. PubMed ID: 30239834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis.
    Are VS; Vuppalanchi R; Vilar-Gomez E; Chalasani N
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1292-1293.e3. PubMed ID: 32629127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin E and nonalcoholic fatty liver disease.
    Pacana T; Sanyal AJ
    Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.
    Omran D; Yosry A; Darweesh SK; Nabeel MM; El-Beshlawey M; Saif S; Fared A; Hassany M; Zayed RA
    Clin Exp Med; 2018 Feb; 18(1):45-50. PubMed ID: 28567544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
    Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
    JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients.
    Fernandes FF; Ferraz ML; Andrade LE; Dellavance A; Terra C; Pereira G; Pereira JL; Campos F; Figueiredo F; Perez RM
    J Clin Gastroenterol; 2015 Mar; 49(3):235-41. PubMed ID: 24714186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.